Nezam El-Tayebat 事实核查对“نظام الطيبات”饮食体系的科学评估
选择国家
选择语言: 简体中文

基本错误 过度解读 证据确定性: 高 初步 C-CHM-09

该档案网站在首页上把其收录的19项化疗/放疗研究介绍为“证实 Diaa 医生观点的科学研究”；这种只收录危害的研究选择暗示化疗和放疗的危害大于获益。

安全提示: 请勿为了饮食疗法而拒绝、停止或推迟推荐的癌症治疗（手术、化疗、放疗、激素治疗或靶向治疗）。对于可治愈的癌症，用替代疗法取代标准治疗与明显更高的死亡风险相关（I-CHM-03、I-CHM-04），即使仅推迟四周也与更高的死亡率相关（I-CHM-07）。远期不良反应确实存在，可通过癌症幸存者随访照护和心脏肿瘤学照护加以处理；请与负责治疗的肿瘤团队讨论。营养方案可在治疗的同时与肿瘤团队一起调整。本页不提供个体化医疗建议。
简而言之: 基本错误：该档案网站列出的副作用是真实的，但高质量的随机对照证据表明，对于有推荐指征的患者，化疗和放疗所避免的死亡远多于它们造成的死亡；只收录危害的研究选择并不支持其暗示的结论。
结论: 有记录的副作用并不能说明化疗和放疗弊大于利；该档案网站的证据中缺少关于获益的部分。
  1. 原始表述
  2. 科学评估
  3. 科学证据详解
  4. 通俗解释
  5. 与该说法相关的研究
  6. 地区背景
  7. 在我的国家适用什么？
  8. 参考文献

原始表述

دراسات علمية تؤكد ما طرحه د. ضياء العوضي

按来源为原话. 译文由本项目提供；以阿拉伯语原文为准。

译文

该档案网站在首页上把其收录的19项化疗/放疗研究介绍为“证实 Diaa 医生观点的科学研究”；这种只收录危害的研究选择暗示化疗和放疗的危害大于获益。

出处

来源状态
档案网站编辑
归属
Archive editors (homepage section heading above the study list)
出处
https://eltayebat.com/
归属的不确定性
Written by archive operators; not attributed to Elawady.
涉及人群

Cancer patients

Elawady 设定的地域限制

none found

科学评估

基本错误 – 该说法的主要部分没有证据支持，或被严重夸大。

证据确定性: 高 – 进一步研究极不可能改变该评估。

1. 说法是什么？

Studies documenting late effects confirm Dr. Diaa's position (which, in his videos, is to avoid chemotherapy and radiotherapy).

2. 哪些内容可证实是正确的？

The late effects are real and correctly reported in most cases (C-CHM-01 to C-CHM-06). The archive narrative itself states that chemotherapy and radiotherapy 'have saved millions of lives' and that its text 'is not a call to refuse treatment' - this is fair and should be acknowledged.

3. 哪些内容是错误或夸大的？

The bibliography quantifies only harms. Several of the archive's own studies report benefits that are not mentioned: trastuzumab halved recurrence and reduced deaths by a third (A-CHM-05); tamoxifen's net benefit 'greatly outweighs' its risk (A-CHM-08); most second cancers are not due to radiotherapy (A-CHM-07); testicular cancer has 95% 10-year survival (A-CHM-14); late mortality halved with modified treatment (A-CHM-11). Independent evidence: modern chemotherapy reduces breast-cancer mortality by about one-third with lower overall mortality (I-CHM-01); radiotherapy halves recurrence (I-CHM-02); alternative-only treatment of curable cancers was associated with a 2.5-fold higher risk of death (I-CHM-03). The harm studies therefore do not 'confirm' a position against these treatments.

4. 哪些内容仍不明确？

Whether readers interpret the page as a recommendation to refuse treatment is not known.

5. 哪些研究支持该说法？

Harms: A-CHM-01..A-CHM-19. Partial support for scepticism: across all adult cancers, cytotoxic chemotherapy alone was estimated to account for about 2% of 5-year survival (I-CHM-123; a population share that includes many patients who never need chemotherapy); many new cancer drugs approved in Europe 2009-13 lacked proof of survival or quality-of-life benefit (I-CHM-124); old-technique postmastectomy radiotherapy increased overall mortality in low-risk node-negative women (RR 1.23, 1.02-1.49; I-CHM-102), which is why guidelines do not offer it to low-risk patients (NICE NG101).

6. 哪些研究与该说法相矛盾？

I-CHM-01, I-CHM-02, I-CHM-03, I-CHM-04, I-CHM-05, I-CHM-12; I-CHM-101 (anthracycline-taxane chemotherapy: fewer recurrences and breast-cancer deaths; about one extra AML per 700 women; no excess non-breast-cancer death); I-CHM-102 (postmastectomy radiotherapy in node-positive women: 20-year breast-cancer mortality 66.4% to 58.3%); A-CHM-05, A-CHM-07, A-CHM-08, A-CHM-14; mixed A-CHM-11.

7. 对德国和欧洲而言情况如何？

Same evidence base applies.

8. 关于埃及的已知情况是什么？

Same evidence base applies.

9. 合理的实际结论是什么？

公正的介绍应在列出远期影响的同时列出获益证据（绝对生存获益）。

评估详情

证据确定性的依据

The archive's own narrative concedes the benefit, but the study list quantifies only harms; high-certainty randomised and registry evidence shows large survival benefits and higher mortality when treatment is replaced.

来源质量

Archive editorial framing.

地区可推广性

High.

说法的地域范围
普遍性（生物学/医学）
最近审核
2026年10月26日 初步

科学证据详解

过度解读 – 确有真实的发现，但该说法从中引申出的结论超出了数据所能支持的范围（例如把关联当作因果、把动物数据套用到人身上、把小效应说成大效应）。

研究问题: In patients for whom chemotherapy or radiotherapy is recommended, do the documented harms outweigh the benefits?

研究问题详解 (PICO)
人群
Patients with cancer for whom chemotherapy or radiotherapy is indicated
干预或暴露
Chemotherapy and/or radiotherapy
对照
No such treatment (same surgery/supportive care)
地域范围
universal clinical evidence; access differs by country
结局指标
  • Overall and cancer-specific mortality
  • Recurrence
  • Treatment-related deaths and second cancers
  • Late effects

研究结果按作者报告呈现。我们的评估见下文。

哪些证据支持该说法？

哪些证据不支持该说法？

总体证据说明了什么？

基于上述研究的编辑评估——其本身并非研究结果。

哪种观点有更好的证据支持？

For patients in whom chemotherapy or radiotherapy is recommended, randomised evidence shows benefits that clearly exceed the documented harms; harms are real and are the reason treatment is risk-adapted.

为什么有些研究权重更大

Randomised IPD meta-analyses directly measure net effect (all-cause mortality); harm-only observational studies cannot. Morgan 2004 and Davis 2017 are legitimate but answer different questions (population share; new drugs).

因果关系是否已确立？ 是，已确立 Randomised comparisons with mortality outcomes.

仍存在的不确定性

Net benefit for low-risk patients and for some new drugs with marginal gains.

合理的结论

The archive's implied conclusion is not supported: documented harms do not show that indicated chemotherapy and radiotherapy do more harm than good.

为什么研究结果看起来互相矛盾？

Harm studies (A-CHM-01..19) and benefit trials do not disagree: the harms are real but smaller in absolute terms than the benefits in indicated patients. Net harm appears only where baseline risk is low (I-CHM-102 node-negative subgroup), which guidelines already exclude (NICE NG101).

这是否取决于国家？
一般生物学效应
Universal clinical evidence.
饮食习惯
Not relevant.
食品原产地
Not relevant.
污染物
Not relevant.
本国生产条件
Not relevant.
法律规则
Treatment availability and guideline adoption differ; not reviewed for Egypt.
实际监测数据
Egyptian childhood survival data (I-CHM-125) show high survival with standard treatment.

足以改变结论的地区差异没有可靠数据支持。

统计复核
  • NNT vs NNH – RT after BCS: NNT 6.4 (recurrence), 26 (breast cancer death), 33 (any death); modern RT NNH about 333 for cardiac death in non-smokers 已重新计算
  • Absolute benefit and subgroup harm – pN+: NNT 9.4 (recurrence), 12.3 (breast cancer death); pN0 overall mortality RR 1.23 (log-symmetric CI) = net harm in low-risk subgroup 已重新计算
  • NNT vs NNH – NNT 11.5 (concurrent regimen, recurrence) vs NNH about 677 (AML) 已重新计算
  • Metric interpretation – 2.3% is a population-weighted share, not an effect size in treated patients; not recalculable from abstract 无法根据已发表数据重新计算
总体证据的确定性（GRADE，简化版）
主要结局
All-cause mortality with indicated chemotherapy/radiotherapy vs none
起始等级
高（随机试验）
结果
高

由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。

已核查的临床指南和官方声明
  • NICE: Early and locally advanced breast cancer: diagnosis and management (NG101) (2018, last updated 14 April 2025) · 原始文献
    Offer whole-breast radiotherapy after breast-conserving surgery with clear margins; offer postmastectomy radiotherapy for node-positive disease or involved margins; do not offer postmastectomy radiotherapy to people at low risk of local recurrence; where adjuvant chemotherapy is indicated, offer a regimen containing a taxane and an anthracycline and discuss benefits and risks.
  • ESMO: Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (Loibl S et al., Ann Oncol 2024; PMID 38101773) (2024) · 原始文献 无法获取；内容未采用
  • WHO: Cancer - fact sheet (2026 (page fetched 2026-10-26)) · 原始文献
    Many cancers can be cured if detected early and treated effectively; treatment usually includes surgery, radiotherapy and/or systemic therapy; some cancers such as testicular seminoma and childhood leukaemias and lymphomas have high cure rates with appropriate treatment even when spread; palliative care relieves symptoms in advanced cancer.
  • NCI: Chemotherapy to Treat Cancer (2026 (fetched 2026-10-26)) · 原始文献
    Chemotherapy can be used to cure cancer, lessen the chance it will return, or stop or slow its growth, and to ease symptoms; it also harms fast-growing healthy cells, causing side effects.
检索策略

本次审查的文献检索记录（检索式采用原数据库语法）。

数据库日期检索式检索目标命中数纳入数
Europe PMC2026年10月26日TITLE:"contribution of cytotoxic chemotherapy to 5-year survival"支持性证据1
Europe PMC2026年10月26日TITLE:"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency"支持性证据2
Europe PMC2026年10月26日(TITLE:"chemotherapy" OR TITLE:"cancer treatment") AND (TITLE:"more harm than good" OR TITLE:"overtreatment" OR TITLE:"futile" OR TITLE:"no survival benefit") AND PUB_YEAR:[2010 TO 2026]支持性证据253
PubMed2026年10月26日(chemotherapy[ti]) AND ("harm"[ti] OR "harms"[ti] OR "overtreatment"[ti]) AND (benefit[ti]) AND (systematic review[pt] OR meta-analysis[pt])支持性证据0
PubMed2026年10月26日"Early Breast Cancer Trialists Collaborative Group"[Corporate Author] AND Lancet[ta] AND 2012:2026[dp]反对性证据12
Europe PMC2026年10月26日TITLE:"Early Breast Cancer Trialists" AND (anthracycline OR taxane OR radiotherapy OR mastectomy) AND PUB_YEAR:[2013 TO 2026]反对性证据2
Europe PMC2026年10月26日TITLE:"chemotherapy" AND TITLE:"supportive care" AND TITLE:"non-small-cell lung cancer" AND (TITLE:"meta-analysis" OR TITLE:"individual patient")反对性证据3
PubMed2026年10月26日ESMO Clinical Practice Guideline[ti] AND early breast cancer[ti] AND 2023:2026[dp]指南1

待解决的问题

Treatment access and outcomes for adults in Egypt.

核查深度如何？

15 项相关研究：7 项核查了全文（其中 5 项进行了结构化偏倚风险评估），8 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。

最近一次科学审核: 2026年10月26日

评定结论的变更历史
  1. 2026年10月25日 · 第 1 阶段 · 初始评估: 基本错误 (高)
  2. 2026年10月26日 · 第 4 阶段（系统证据审查） · 在扩展证据后重新审查；评定结论不变: 基本错误 (高)
    New IPD meta-analyses strengthen the benefit side; Morgan 2004 and Davis 2017 add legitimate nuance (small population share; uncertain benefit of some new drugs) but do not show net harm for indicated treatment. Verdict and certainty unchanged.
    新来源: I-CHM-101 I-CHM-102 I-CHM-123 I-CHM-124

通俗解释

该档案网站关于化疗和放疗的研究清单展示了真实存在的副作用：心脏损伤、第二原发癌、听力损失等。该档案网站的文字也承认这些治疗能挽救生命。但这份清单中没有任何一项研究衡量了挽救了多少生命，而首页却把这些研究称为对 Diaa 医生观点的证实。大型试验表明，化疗和放疗能在许多癌症中明显减少死亡，而用替代方法取代这些治疗的人死亡更多。

与该说法相关的研究

支持该说法的研究 (0)

该组中没有研究。

与该说法相矛盾或限制该说法的研究 (12)

  • Chemotherapy after breast-cancer surgery reduces deaths by about a third

    EBCTCG. Lancet 2012 · PMID 22152853 · DOI 10.1016/S0140-6736(11)61625-5
    Meta分析独立交叉核查全文，含结构化偏倚风险评估★ 关键研究

    In 123 trials with 100,000 women, modern regimens cut breast-cancer deaths by about one-third, and overall deaths fell too.

    Benefit omitted

    该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Compare chemotherapy regimens and no chemotherapy.

    研究是如何开展的？

    IPD meta-analysis of RCTs.

    研究了多少人、动物或样本？

    ~100,000 women.

    实际发现了什么？

    ~1/3 lower breast-cancer mortality.

    观察到的效应有多大？

    RR 0.64-0.78 vs none.

    研究结果对日常生活意味着什么？

    For many women, chemotherapy substantially raises the chance of survival.

    该研究有哪些局限？

    Trials versus no chemotherapy are old (median start 1986); a small excess of non-breast-cancer deaths (e.g. heart, leukaemia) occurred; benefit is small when baseline risk is low.

    它对 Elawady 的具体说法说明了什么？

    Contradicts claims that chemotherapy is useless.

    研究结果是否适用于德国和欧洲？

    High.

    从该研究中明确不能得出什么结论？

    Individual benefit without risk assessment.

    科学细节 →

  • Radiotherapy after breast-conserving surgery halves recurrence

    EBCTCG. Lancet 2011 · PMID 22019144 · DOI 10.1016/S0140-6736(11)61629-2
    Meta分析独立交叉核查全文，含结构化偏倚风险评估★ 关键研究

    Recurrence within 10 years fell from 35% to 19%, and breast-cancer deaths within 15 years from 25% to 21%.

    Benefit omitted

    该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Measure radiotherapy benefit.

    研究是如何开展的？

    IPD meta-analysis.

    研究了多少人、动物或样本？

    10,801 women.

    实际发现了什么？

    Recurrence halved; breast-cancer deaths about one-sixth lower; deaths from any cause at 15 years 3.0 percentage points lower.

    观察到的效应有多大？

    -15.7% recurrence; -3.8% death.

    研究结果对日常生活意味着什么？

    Radiotherapy markedly lowers the chance the cancer returns.

    该研究有哪些局限？

    Older techniques; risk groups derived from the same data; in low-risk node-negative women the gain in survival was small and uncertain.

    它对 Elawady 的具体说法说明了什么？

    Benefit side.

    研究结果是否适用于德国和欧洲？

    High.

    从该研究中明确不能得出什么结论？

    Individual benefit size without risk factors.

    科学细节 →

  • Patients who used only alternative medicine for curable cancer died more often

    Johnson SB et al.. J Natl Cancer Inst 2018 · PMID 28922780 · DOI 10.1093/jnci/djx145
    队列研究独立交叉核查已核查摘要★ 关键研究

    Risk of death was 2.5 times higher overall and 5.7 times higher for breast cancer.

    Refusing treatment costs lives

    该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Compare AM-only vs conventional treatment.

    研究是如何开展的？

    Matched registry cohort.

    研究了多少人、动物或样本？

    840 matched patients.

    实际发现了什么？

    HR 2.50 for death.

    观察到的效应有多大？

    HR 5.68 breast cancer.

    研究结果对日常生活意味着什么？

    Replacing cancer treatment with alternatives is dangerous.

    该研究有哪些局限？

    Observational.

    它对 Elawady 的具体说法说明了什么？

    Contradicts refusing therapy.

    研究结果是否适用于德国和欧洲？

    Moderate.

    从该研究中明确不能得出什么结论？

    Effects of complementary approaches used alongside treatment.

    科学细节 →

  • Refusing standard cancer treatment, not complementary medicine itself, raised the risk of death

    Johnson SB et al.. JAMA Oncol 2018 · PMID 30027204 · DOI 10.1001/jamaoncol.2018.2487
    队列研究独立交叉核查已核查摘要★ 关键研究

    Users of complementary medicine refused chemotherapy or radiotherapy far more often and had about twice the risk of death.

    Benefit of adherence

    该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Study CM and survival.

    研究是如何开展的？

    Registry cohort.

    研究了多少人、动物或样本？

    258 vs 1,032.

    实际发现了什么？

    HR 2.08; explained by refusal.

    观察到的效应有多大？

    5-y OS 82.2% vs 86.6%.

    研究结果对日常生活意味着什么？

    Diet or other approaches alongside treatment are not the problem; replacing treatment is.

    该研究有哪些局限？

    Observational.

    它对 Elawady 的具体说法说明了什么？

    Contradicts refusal advice.

    研究结果是否适用于德国和欧洲？

    Moderate.

    从该研究中明确不能得出什么结论？

    Causal effect of any single CM.

    科学细节 →

  • About 9 in 10 children with leukaemia now survive

    Hunger SP et al.. J Clin Oncol 2012 · PMID 22412151 · DOI 10.1200/JCO.2011.37.8018
    队列研究独立交叉核查已核查摘要★ 关键研究

    5-year survival in childhood ALL rose to 90.4% by 2000-2005.

    Benefit omitted

    该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Track ALL survival.

    研究是如何开展的？

    Trial cohort analysis.

    研究了多少人、动物或样本？

    21,626.

    实际发现了什么？

    83.7% -> 90.4%.

    观察到的效应有多大？

    +6.7 points.

    研究结果对日常生活意味着什么？

    Childhood leukaemia is usually curable with treatment.

    该研究有哪些局限？

    Trial patients.

    它对 Elawady 的具体说法说明了什么？

    Benefit side.

    研究结果是否适用于德国和欧洲？

    Moderate.

    从该研究中明确不能得出什么结论？

    Survival outside trials.

    科学细节 →

  • Cancer death rates in the USA keep falling

    Siegel RL et al.. CA Cancer J Clin 2024 · PMID 38230766 · DOI 10.3322/caac.21820
    其他独立交叉核查已核查摘要

    More than 4 million cancer deaths averted since 1991 thanks to less smoking, earlier detection and better treatment.

    Treatment contributes to falling mortality

    该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Report cancer statistics.

    研究是如何开展的？

    Registry data.

    研究了多少人、动物或样本？

    US population.

    实际发现了什么？

    Declining mortality.

    观察到的效应有多大？

    >4 million deaths averted.

    研究结果对日常生活意味着什么？

    Prevention and treatment both work.

    该研究有哪些局限？

    Descriptive.

    它对 Elawady 的具体说法说明了什么？

    Benefit context.

    研究结果是否适用于德国和欧洲？

    Moderate.

    从该研究中明确不能得出什么结论？

    Share due to treatment alone.

    科学细节 →

  • Adding trastuzumab to chemotherapy halved recurrence in HER2-positive breast cancer

    Romond EH et al.. N Engl J Med 2005 · PMID 16236738 · DOI 10.1056/NEJMoa052122
    随机对照试验被 Tayebat 档案网站引用已核查摘要★ 关键研究

    Fewer recurrences and a third fewer deaths; serious heart problems in about 3-4 in 100 treated women.

    Main result is benefit (HR 0.48; 33% fewer deaths)

    该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Test trastuzumab added to chemotherapy.

    研究是如何开展的？

    Two RCTs analysed jointly.

    研究了多少人、动物或样本？

    Operable HER2+ breast cancer.

    实际发现了什么？

    HR 0.48 for events; 33% fewer deaths.

    观察到的效应有多大？

    +12% absolute DFS at 3 years.

    研究结果对日常生活意味着什么？

    Benefit clearly exceeds the cardiac risk for most patients; heart monitoring is needed.

    该研究有哪些局限？

    Interim analysis.

    它对 Elawady 的具体说法说明了什么？

    Documents harm and much larger benefit.

    研究结果是否适用于德国和欧洲？

    High.

    从该研究中明确不能得出什么结论？

    That treatment should be avoided.

    科学细节 →

  • Only a small share of second cancers in adults is caused by radiotherapy

    Berrington de Gonzalez A et al.. Lancet Oncol 2011 · PMID 21454129 · DOI 10.1016/S1470-2045(11)70061-4
    队列研究被 Tayebat 档案网站引用全文，含结构化偏倚风险评估★ 关键研究

    About 5 extra cancers per 1,000 treated patients within 15 years; 8% of second cancers in irradiated patients.

    Authors conclude most second cancers are not due to RT

    该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Estimate radiotherapy-attributable second cancers.

    研究是如何开展的？

    SEER cohort.

    研究了多少人、动物或样本？

    647,672 survivors.

    实际发现了什么？

    8% attributable; 5/1000 by 15 years.

    观察到的效应有多大？

    RR 1.08-1.43.

    研究结果对日常生活意味着什么？

    The risk is real but small compared with the benefit of cure.

    该研究有哪些局限？

    No randomisation; no data on smoking, chemotherapy or doses; treatments before 2003.

    它对 Elawady 的具体说法说明了什么？

    Limits the 'heavy price' framing.

    研究结果是否适用于德国和欧洲？

    High.

    从该研究中明确不能得出什么结论？

    Risk for an individual patient.

    科学细节 →

  • Tamoxifen raises the small risk of uterine cancer but prevents far more breast-cancer events

    Fisher B et al.. J Natl Cancer Inst 1994 · PMID 8133536 · DOI 10.1093/jnci/86.7.527
    随机对照试验被 Tayebat 档案网站引用已核查摘要

    Uterine cancer about 1.6 vs 0.2 per 1,000 women per year; 38% fewer recurrence-type events.

    Authors: net benefit greatly outweighs risk

    该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Assess second cancers under tamoxifen.

    研究是如何开展的？

    RCT vs placebo.

    研究了多少人、动物或样本？

    2,843 + 1,220.

    实际发现了什么？

    RR 7.5 endometrial cancer; benefit outweighs.

    观察到的效应有多大？

    1.6 vs 0.2/1000/year.

    研究结果对日常生活意味着什么？

    Report abnormal bleeding during tamoxifen; continue therapy.

    该研究有哪些局限？

    Few events; data-integrity issue.

    它对 Elawady 的具体说法说明了什么？

    Mixed.

    研究结果是否适用于德国和欧洲？

    High.

    从该研究中明确不能得出什么结论？

    That tamoxifen is net harmful.

    科学细节 →

  • Testicular cancer survivors face late effects but almost all survive

    Fung C et al.. Adv Urol 2018 · PMID 29670654 · DOI 10.1155/2018/8671832
    叙述性综述被 Tayebat 档案网站引用全文，含结构化偏倚风险评估

    10-year relative survival is 95%; heart disease and second cancers are the main serious late effects.

    95% 10-year relative survival

    该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 低 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Review late effects.

    研究是如何开展的？

    Narrative review.

    实际发现了什么？

    Multiple late effects.

    研究结果对日常生活意味着什么？

    Long-term check-ups and healthy lifestyle.

    该研究有哪些局限？

    Narrative review without systematic search or quality appraisal; much evidence from older treatment eras.

    它对 Elawady 的具体说法说明了什么？

    Mixed.

    研究结果是否适用于德国和欧洲？

    High.

    从该研究中明确不能得出什么结论？

    Quantitative risks.

    科学细节 →

  • Chemotherapy for early breast cancer: benefits and risks in 100,000 women

    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet 2023 · PMID 37061269 · DOI 10.1016/S0140-6736(23)00285-4
    Meta分析独立交叉核查已核查全文★ 关键研究

    Anthracycline-taxane chemotherapy lowered recurrence and breast-cancer death; it caused about one extra leukaemia per 700 women and no measurable excess heart deaths within about 5 years.

    Benefit of chemotherapy clearly exceeds the measured harms in randomised data.

    该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Weigh benefits and risks of anthracycline-containing chemotherapy

    研究是如何开展的？

    Pooled individual data from randomised trials

    研究了多少人、动物或样本？

    18,103 women in the main comparison; about 100,000 overall

    实际发现了什么？

    Fewer recurrences (RR 0.86) and fewer breast-cancer deaths; AML 0.18% vs 0.03%

    观察到的效应有多大？

    10-year recurrence 16.4% vs 18.9%; up to 8.7 points fewer recurrences with concurrent anthracycline

    研究结果对日常生活意味着什么？

    For every leukaemia caused, roughly 18 recurrences are prevented in this data set

    该研究有哪些局限？

    Short follow-up for heart effects; high-risk heart patients often excluded

    它对 Elawady 的具体说法说明了什么？

    Harms of chemotherapy are real (AML) but small compared with the benefit; this contradicts the idea that harms outweigh benefits

    研究结果是否适用于德国和欧洲？

    High

    从该研究中明确不能得出什么结论？

    Cannot quantify heart failure 15-20 years after treatment

    科学细节 →

  • Radiotherapy after breast removal: 20-year results of 22 trials

    EBCTCG; McGale P et al.. Lancet 2014 · PMID 24656685 · DOI 10.1016/S0140-6736(14)60488-8
    Meta分析独立交叉核查已核查全文★ 关键研究

    In women with cancer in the lymph nodes, radiotherapy prevented about 1 in 10 recurrences and about 1 in 12 breast-cancer deaths; in low-risk women with old techniques it did more harm than good.

    Radiotherapy lowers recurrence and breast-cancer death in node-positive women; also documents net harm in low-risk women, which supports risk-adapted use, not refusal.

    该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Test whether radiotherapy after mastectomy saves lives

    研究是如何开展的？

    Pooled individual data from 22 randomised trials

    研究了多少人、动物或样本？

    8135 women, 1964-86

    实际发现了什么？

    Benefit in node-positive disease; overall mortality increase in node-negative women after full axillary surgery

    观察到的效应有多大？

    pN+: recurrence 62.5% -> 51.9%; breast-cancer death 66.4% -> 58.3%

    研究结果对日常生活意味着什么？

    Radiotherapy helps when recurrence risk is substantial and can harm when it is low

    该研究有哪些局限？

    Old techniques; modern doses are lower

    它对 Elawady 的具体说法说明了什么？

    Contradicts blanket claims that radiotherapy does more harm than good; supports careful selection

    研究结果是否适用于德国和欧洲？

    Moderate to high

    从该研究中明确不能得出什么结论？

    Cannot give exact absolute benefits for today's patients

    科学细节 →

结果不一或不明确的研究 (3)

  • Late deaths among childhood-cancer survivors have fallen as treatment became gentler

    Armstrong GT et al.. N Engl J Med 2016 · PMID 26761625 · DOI 10.1056/NEJMoa1510795
    队列研究被 Tayebat 档案网站引用全文，含结构化偏倚风险评估★ 关键研究

    15-year death rate after surviving 5 years dropped from 12.4% to 6.0% between the 1970s and 1990s.

    Oncology reduces late effects

    该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Track late mortality across eras.

    研究是如何开展的？

    Cohort, 34,033 survivors.

    研究了多少人、动物或样本？

    34,033.

    实际发现了什么？

    41% of late deaths health-related; mortality halved over time.

    观察到的效应有多大？

    12.4% -> 6.0%.

    研究结果对日常生活意味着什么？

    Late effects are real and being reduced.

    该研究有哪些局限？

    Observational era comparison; cannot measure improvements in medical care; treatment data imputed for 29%; shorter follow-up for the 1990s.

    它对 Elawady 的具体说法说明了什么？

    Supports burden and shows progress.

    研究结果是否适用于德国和欧洲？

    Moderate.

    从该研究中明确不能得出什么结论？

    That treatment should be avoided.

    科学细节 →

  • How much does chemotherapy add to cancer survival overall?

    Morgan G et al.. Clin Oncol (R Coll Radiol) 2004 · PMID 15630849 · DOI 10.1016/j.clon.2004.06.007
    其他独立交叉核查已核查摘要★ 关键研究

    Across all adult cancer patients, the authors estimated that about 2% are alive at 5 years because of chemotherapy alone.

    Supports that cytotoxic chemotherapy contributes a small share of population cancer survival; does not support 'harms outweigh benefits' for indicated patients.

    该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 低 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Estimate population-level contribution of chemotherapy

    研究是如何开展的？

    Modelling from trials and registries

    研究了多少人、动物或样本？

    22 cancer types

    实际发现了什么？

    About 2.3% of all patients

    观察到的效应有多大？

    2.1-2.3%

    研究结果对日常生活意味着什么？

    Chemotherapy is not the main reason most people survive cancer (surgery and early detection are)

    该研究有哪些局限？

    Denominator includes patients who never needed chemotherapy

    它对 Elawady 的具体说法说明了什么？

    Gives partial support to scepticism, but not to refusing indicated treatment

    研究结果是否适用于德国和欧洲？

    Low

    从该研究中明确不能得出什么结论？

    Cannot show chemotherapy is useless for a given patient

    科学细节 →

  • Many new cancer drugs approved without proof of longer or better life

    Davis C et al.. BMJ 2017 · PMID 28978555 · DOI 10.1136/bmj.j4530
    其他独立交叉核查已核查摘要

    Of 68 new cancer-drug approvals in Europe, only about half showed a survival or quality-of-life benefit after 5 years.

    Shows that benefit of some new cancer drugs is unproven or marginal; does not apply to proven curative regimens.

    该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Check evidence behind new cancer drugs

    研究是如何开展的？

    Cohort of EMA approvals

    研究了多少人、动物或样本？

    68 indications 2009-13

    实际发现了什么？

    Many approvals with uncertain benefit

    观察到的效应有多大？

    35% had OS benefit at approval

    研究结果对日常生活意味着什么？

    Ask what a new drug adds; proven standard treatments are different

    该研究有哪些局限？

    New drugs only

    它对 Elawady 的具体说法说明了什么？

    Partly supports scepticism

    研究结果是否适用于德国和欧洲？

    High

    从该研究中明确不能得出什么结论？

    Does not apply to established curative chemotherapy or radiotherapy

    科学细节 →

地区背景

德国 / 欧盟

Same evidence base applies.

埃及

Same evidence base applies.

在我的国家适用什么？

一般科学评估

基本错误 有记录的副作用并不能说明化疗和放疗弊大于利；该档案网站的证据中缺少关于获益的部分。

该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。

参考文献

  1. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.. EBCTCG. Lancet 2012 · PMID 22152853 · DOI 10.1016/S0140-6736(11)61625-5
  2. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.. EBCTCG. Lancet 2011 · PMID 22019144 · DOI 10.1016/S0140-6736(11)61629-2
  3. Use of Alternative Medicine for Cancer and Its Impact on Survival.. Johnson SB et al.. J Natl Cancer Inst 2018 · PMID 28922780 · DOI 10.1093/jnci/djx145
  4. Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers.. Johnson SB et al.. JAMA Oncol 2018 · PMID 30027204 · DOI 10.1001/jamaoncol.2018.2487
  5. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.. Hunger SP et al.. J Clin Oncol 2012 · PMID 22412151 · DOI 10.1200/JCO.2011.37.8018
  6. Cancer statistics, 2024.. Siegel RL et al.. CA Cancer J Clin 2024 · PMID 38230766 · DOI 10.3322/caac.21820
  7. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.. Romond EH et al.. N Engl J Med 2005 · PMID 16236738 · DOI 10.1056/NEJMoa052122
  8. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries.. Berrington de Gonzalez A et al.. Lancet Oncol 2011 · PMID 21454129 · DOI 10.1016/S1470-2045(11)70061-4
  9. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.. Fisher B et al.. J Natl Cancer Inst 1994 · PMID 8133536 · DOI 10.1093/jnci/86.7.527
  10. Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors.. Fung C et al.. Adv Urol 2018 · PMID 29670654 · DOI 10.1155/2018/8671832
  11. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet 2023 · PMID 37061269 · DOI 10.1016/S0140-6736(23)00285-4
  12. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.. EBCTCG; McGale P et al.. Lancet 2014 · PMID 24656685 · DOI 10.1016/S0140-6736(14)60488-8
  13. Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer.. Armstrong GT et al.. N Engl J Med 2016 · PMID 26761625 · DOI 10.1056/NEJMoa1510795
  14. The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies.. Morgan G et al.. Clin Oncol (R Coll Radiol) 2004 · PMID 15630849 · DOI 10.1016/j.clon.2004.06.007
  15. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.. Davis C et al.. BMJ 2017 · PMID 28978555 · DOI 10.1136/bmj.j4530

← 返回概览